GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000734619 | Thyroid | PTC | regulation of mitotic cell cycle | 212/5968 | 457/18723 | 4.03e-11 | 1.44e-09 | 212 |
GO:0071496113 | Thyroid | PTC | cellular response to external stimulus | 158/5968 | 320/18723 | 4.12e-11 | 1.47e-09 | 158 |
GO:000726519 | Thyroid | PTC | Ras protein signal transduction | 162/5968 | 337/18723 | 3.16e-10 | 1.02e-08 | 162 |
GO:004477218 | Thyroid | PTC | mitotic cell cycle phase transition | 196/5968 | 424/18723 | 3.17e-10 | 1.02e-08 | 196 |
GO:0048545113 | Thyroid | PTC | response to steroid hormone | 158/5968 | 339/18723 | 8.10e-09 | 2.00e-07 | 158 |
GO:0031668113 | Thyroid | PTC | cellular response to extracellular stimulus | 120/5968 | 246/18723 | 2.13e-08 | 4.91e-07 | 120 |
GO:003052228 | Thyroid | PTC | intracellular receptor signaling pathway | 126/5968 | 265/18723 | 6.31e-08 | 1.31e-06 | 126 |
GO:0031669112 | Thyroid | PTC | cellular response to nutrient levels | 106/5968 | 215/18723 | 6.96e-08 | 1.44e-06 | 106 |
GO:19019908 | Thyroid | PTC | regulation of mitotic cell cycle phase transition | 138/5968 | 299/18723 | 1.44e-07 | 2.78e-06 | 138 |
GO:0030518111 | Thyroid | PTC | intracellular steroid hormone receptor signaling pathway | 63/5968 | 116/18723 | 4.53e-07 | 7.41e-06 | 63 |
GO:0031667113 | Thyroid | PTC | response to nutrient levels | 201/5968 | 474/18723 | 7.00e-07 | 1.10e-05 | 201 |
GO:000182215 | Thyroid | PTC | kidney development | 133/5968 | 293/18723 | 7.57e-07 | 1.18e-05 | 133 |
GO:00000829 | Thyroid | PTC | G1/S transition of mitotic cell cycle | 102/5968 | 214/18723 | 9.48e-07 | 1.43e-05 | 102 |
GO:0071383112 | Thyroid | PTC | cellular response to steroid hormone stimulus | 98/5968 | 204/18723 | 9.83e-07 | 1.47e-05 | 98 |
GO:00448439 | Thyroid | PTC | cell cycle G1/S phase transition | 112/5968 | 241/18723 | 1.37e-06 | 1.96e-05 | 112 |
GO:000165517 | Thyroid | PTC | urogenital system development | 149/5968 | 338/18723 | 1.41e-06 | 2.01e-05 | 149 |
GO:007200114 | Thyroid | PTC | renal system development | 135/5968 | 302/18723 | 1.76e-06 | 2.43e-05 | 135 |
GO:00457867 | Thyroid | PTC | negative regulation of cell cycle | 166/5968 | 385/18723 | 1.93e-06 | 2.64e-05 | 166 |
GO:19019878 | Thyroid | PTC | regulation of cell cycle phase transition | 167/5968 | 390/18723 | 2.97e-06 | 3.87e-05 | 167 |
GO:0001667112 | Thyroid | PTC | ameboidal-type cell migration | 198/5968 | 475/18723 | 3.36e-06 | 4.34e-05 | 198 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KANK2 | SNV | Missense_Mutation | rs754387207 | c.1769C>T | p.Thr590Met | p.T590M | Q63ZY3 | protein_coding | tolerated(0.1) | benign(0) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KANK2 | SNV | Missense_Mutation | rs751868507 | c.1424N>T | p.Pro475Leu | p.P475L | Q63ZY3 | protein_coding | tolerated(0.37) | benign(0) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KANK2 | insertion | Frame_Shift_Ins | novel | c.314_315insGTGG | p.Gly106TrpfsTer127 | p.G106Wfs*127 | Q63ZY3 | protein_coding | | | TCGA-XR-A8TG-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
KANK2 | insertion | In_Frame_Ins | novel | c.312_313insGGCGTCCGTGGGAATGAGCTGGTGGTCCCGGCACGGCTG | p.Gly104_Arg105insGlyValArgGlyAsnGluLeuValValProAlaArgLeu | p.G104_R105insGVRGNELVVPARL | Q63ZY3 | protein_coding | | | TCGA-XR-A8TG-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
KANK2 | SNV | Missense_Mutation | rs753499942 | c.1435C>T | p.Pro479Ser | p.P479S | Q63ZY3 | protein_coding | tolerated(0.74) | benign(0.015) | TCGA-53-7624-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
KANK2 | SNV | Missense_Mutation | | c.2095N>T | p.Val699Phe | p.V699F | Q63ZY3 | protein_coding | deleterious(0.01) | benign(0.408) | TCGA-55-8302-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
KANK2 | SNV | Missense_Mutation | | c.1111N>T | p.Gly371Cys | p.G371C | Q63ZY3 | protein_coding | deleterious(0.02) | possibly_damaging(0.694) | TCGA-91-6828-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
KANK2 | SNV | Missense_Mutation | | c.1698C>A | p.Ser566Arg | p.S566R | Q63ZY3 | protein_coding | tolerated(0.27) | benign(0.347) | TCGA-18-5592-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
KANK2 | SNV | Missense_Mutation | rs753499942 | c.1435N>T | p.Pro479Ser | p.P479S | Q63ZY3 | protein_coding | tolerated(0.74) | benign(0.015) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
KANK2 | SNV | Missense_Mutation | rs768289917 | c.314N>A | p.Arg105His | p.R105H | Q63ZY3 | protein_coding | deleterious(0.02) | probably_damaging(0.994) | TCGA-21-5782-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |